Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response

Hepatology. 2010 May;51(5):1505-13. doi: 10.1002/hep.23502.

Abstract

Fibrinogen-beta (FBG-beta), an important acute-phase protein (APP), is generated by the liver as a target for inflammatory mediators. Here we identified FBG-beta as a hepatitis C virus (HCV) core interacting protein by screening a human liver complementary DNA (cDNA) library using mammalian two-hybrid analysis. An association between FBG-beta and HCV core protein was verified by confocal microscopy and coimmunoprecipitation from the transfected human hepatocyte (Huh-7) cell line. HCV core or genomic RNA transfected Huh-7 cells modestly increased FBG-beta protein expression when compared to the basal level in control hepatocytes. Transfection of HCV core or full-length (FL) gene into Huh-7 cells up-regulated basal FBG-beta promoter activity. Exogenous addition of IL-6 stimulates FBG-beta promoter activity in hepatocytes. However, ectopic expression of HCV core or FL in hepatocytes inhibited IL-6-stimulated FBG-beta promoter activation. Inhibition of endogenous FBG-beta expression following introduction of small interfering RNA (siRNA) into cells displayed a gain of function of promoter regulation by HCV core protein. Further studies suggested that HCV core gene expression in stable transfectants of Huh-7 cells resulted in a basal up-regulation of FBG-beta and other APPs. However, treatment with cytokines, interleukin-6 (IL-6), or tumor necrosis factor-alpha repressed FBG-beta and other acute-phase response (APR) genes.

Conclusion: Our results reveal that the core/FBG-beta interaction may act as a regulatory feedback, allowing repression of IL-6-stimulated APR genes. Together, these data suggested a network of interactions between HCV core and the hepatic APR genes, and may contribute to impaired innate immunity for viral persistence.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute-Phase Reaction / drug therapy*
  • Cell Line
  • Fibrinogen / antagonists & inhibitors
  • Fibrinogen / biosynthesis
  • Fibrinogen / metabolism*
  • Hepacivirus / physiology*
  • Hepatocytes
  • Humans
  • Interleukin-6 / pharmacology
  • Protein Interaction Mapping
  • Protein Subunits / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology
  • Two-Hybrid System Techniques
  • Viral Core Proteins / metabolism*

Substances

  • Interleukin-6
  • Protein Subunits
  • Tumor Necrosis Factor-alpha
  • Viral Core Proteins
  • nucleocapsid protein, Hepatitis C virus
  • Fibrinogen